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Objective. Pregnant women affected by SLE are at high risk of gestational hypertension and pre-eclampsia (32–50%). This risk is particularly
elevated if aPLs are dosable. The present study was planned to evaluate maternal–fetal outcomes of different groups of SLE pregnant
patients characterized by diverse risk factors: patients affected by APS treated with a combination of low-dose aspirin (LDA) and
low-molecular weight heparin (LMWH), nulliparous patients with dosable aPL treated by LMWH and SLE patients with no aPL administered
no treatment during pregnancy.
Methods. A retrospective description of maternal and fetal outcomes was made in a total of 62 pregnancies presenting APS in 8 cases
(12.9%), aPL in 20 (32.2%) and no aPL in 34 (54.8%).
Results. No statistically significant difference was found comparing fetal and maternal outcomes of the three groups despite differences
in SLE activity: SLE aPL-positive pregnancies were associated with a higher incidence of nephritis and chronic hypertension than
pregnancies treated for APS or not presenting with the added risk factor. The incidence of pre-eclampsia is 15% in aPL positive, 12.5%
in APS and 14.7% in no aPL pregnancies, respectively.
Conclusions. LMWH is rather a possible option of prophylaxis for SLE aPL-positive pregnancies with potential maternal–fetal outcomes
similar to aPL-negative patients or to standard treated APS.
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Gestational hypertension, Pre-eclampsia, Low molecular weight, Heparin.
Introduction
SLE is a systemic inflammatory disease of unknown aetiology
with a polymorphic clinical picture characterized by the presence
of autoantibodies against a large number of tissue components,
principally directed towards cellular nucleus antigens.
SLE is prevalent in women with an incidence peak in
childbearing age. In SLE, no known fertility reduction is reported
except for patients with severe renal insufficiency, or premature
ovarian failure produced by immunosuppressive drugs, such as
cyclophosphamide [1]. Some studies, addressing the problem if
and how pregnancy may affect the disease, have led to contro-
versial conclusions, in particular concerning the incidence of flare
and organ involvement [1–4]. On the other hand, SLE effects on
the course of pregnancy are well documented in literature. In fact,
despite that the advances in medical, obstetric and neonatal
management have slightly improved pregnancy outcome, SLE still
remains associated with significant maternal and fetal morbidity,
like spontaneous miscarriage, pre-eclampsia, intrauterine growth
restriction (IUGR), fetal death and pre-term delivery [2].
Many studies have attempted to define the pathogenetic process
responsible for the perinatal outcome in SLE pregnant patients.
The following factors have been found of relevance: disease
activity at the time of conception, presence of lupus nephritis,
of aPLs, of anti-SSA/Ro or anti-SSB/La antibodies and pre-
pregnancy maternal hypertension [3]. Nevertheless, the patho-
genetic mechanism remains unknown.
Above all, the role of aPLs, reported in 30–80% of the affected
patients, seems to be particularly important, since they could be
responsible for both maternal thromboembolic disease and
placental insufficiency with pre-term labour, IUGR, pre-
eclampsia and eventually fetal death [4–7].
In the majority of previous studies, SLE pregnant patients with
aPL were untreated while patients with APS only were treated [5].
Moreover, most studies were retrospective involving small groups
of SLE pregnant women with APS, recruited over a large time span
and receiving different treatments (steroids, heparin, aspirin) [5, 8].
We conducted a retrospective study to evaluate maternal and
fetal outcomes in three groups of SLE pregnant patients: one
group of primigravid patients positive to aPLs treated with low-
molecular weight heparin (LMWH) prophylaxis, a second of
patients affected by APS and treated with LMWH and low-dose
aspirin (LDA), and a third one without aPLs and no treatment.
Materials and methods
The study included 58 patients with SLE (for a total of 62
pregnancies) referred to the High-risk Pregnancy Unit of the
Department of Gynaecology, University of Florence, between
January 1998 and June 2006.
All patients were seen in the pre-conceptional phase, and met at
least four of the revised criteria for SLE [9]. In this phase, all
patients were advised to plan pregnancy after at least 6 months of
low disease activity.
At baseline, patients’ medical, clinical and laboratory history
was taken together with maternal informations, including
personal data, obstetric antecedents, duration of SLE, previous
and current SLE manifestations and previous therapy.
During pregnancy patients were seen every 4 weeks until the
27th week and on a weekly basis thereafter, until delivery. In the
post-partum period the patients were seen monthly for 3 months.
Baseline laboratory data included an initial assessment
(followed by monthly control tests) consisting of: complete
blood count, serum creatinine, protein, albumin, glucose and
uric acid, urinalysis and 24-h urine protein excretion. The initial
immunological evaluation included the determination of LAC,
aCLs and a panel of autoantibodies (anti-B2-glycoprotein I, anti-
Ro/SSA, La/SSB and anti-SM). Every trimester the following
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immunological tests were evaluated: C3, C4, CH50, direct and
indirect Coombs test, anti-dsDNA and ANA.
LAC and aCLs (IgG and IgM) were obtained from all patients
prior to conception. LAC screening was performed by coagulation
assays using a LAC-sensitive activated partial thromboplastin
time (aPTT), dilute Russell’s viper venom time (dRVVT) and
kaolin clotting time (KCT). LAC presence was confirmed by the
correction of the extended clotting time with high concentration of
phospholipids. The aCLs were measured by a commercially
available ELISA (First Cardiolipina, Eurospital, Trieste, Italy).
Patients were considered to have aPL if LAC or aCLs were
present in two or more occasions at least 6 weeks apart, as defined
by the international consensus statement [10]. The aCLs were
considered to be positive if there were moderate or high levels of
IgG and/or IgM (>20 GPL or MPL units).
Flare activity was scored before and after pregnancy with the
SLEDAI [11]. Flare was defined as every clinical manifesta-
tion of activity with or without new onset or worsening of
leukopenia, thrombocytopenia, Coombs positive haemolytic
anaemia, proteinuria and an increased serum level of anti-
dsDNA antibodies or a decreased level of serum C3 and C4.
Regarding the fetal examination, routine ultrasound scans
were performed (in the first trimester for dating the pregnancy,
in the second trimester for the fetal anatomy). From the 22nd
week the pregnancy was monitored by further ultrasound scans
to control blood flow velocimetry of uterine arteries (22–24
weeks), umbilical arteries (every month) and fetal growth (every
month); fetal echocardiography was performed in all cases at
17–18 weeks’ gestation, and then repeated at 24 and 30 weeks in
patients with anti-SSA and/or anti-SSB antibodies. From 36
weeks onwards, a cardiotocography (CTG) was performed on a
weekly basis. In case of IUGR, APS, flare, hypertension or
worsening of renal functionality, CTG tracings were started
earlier as appropriate.
The patients with APS received, after confirming the pregnancy
with a urine pregnancy test (levels of HCG >50 IU/ml), LDA
(100mg/day) and LMWH (dalteparin 5000 IU/day s.c.), upon
visualization of embryonic cardiac activity (at 5–6 weeks’
gestation) using conventional transvaginal ultrasound. Aspirin
was under normal circumstances suspended at 34, or earlier in
case of miscarriage or onset of pre-term labour.
Nulliparous patients with aPL received LMWH (dalteparin
5000 IU/day s.c.), upon visualization of embryonic cardiac
activity (at 5–6 weeks’ gestation) using conventional transvaginal
ultrasound. The group of patients negative for aPL were not
treated.
All studied patients were treated until the conception period
with low dose prednisone (5mg/day) and during flare the dose of
prednisone was increased according to the patient’s weight.
All patients were supplemented with iron and vitamins; calcium
carbonate (1.5 g/day) was prescribed in women receiving LMWH.
Negative maternal outcome was considered as one or more of
the following events: miscarriage (spontaneous loss before 10
weeks’ gestation), pre-eclampsia (systolic blood pressure
>140mmHg or diastolic blood pressure >90mmHg associated
with proteinuria >300mg/24 h), lupus flare, and therapeutic
termination of pregnancy because of flare.
The following parameters of perinatal outcome for live births
were considered: pre-term labour (live birth before 37 weeks’
gestation), IUGR (birth weight <10th percentile of the standard
growth curve), birth weight, Apgar index at 1 and 5min and
neonatal ponderal index (PI, defined as the ratio between weight
in grams and height in centimetres  100), which is a gestation-
and gender-independent dimensionless variable, which reflects the
greater impact of protein-calorie malnutrition (intrauterine
growth restriction) on muscle and fat mass when compared with
skeletal growth [12]. Newborns with a PI <2.32 may be considered
nutritionally deprived [13].
Statistical analysis
The quantitative variables have been estimated with the Student’s
t-test, while the qualitative variables have been calculated with the
2-test. A P-value of <0.05 was considered statistically significant.
Results
The demographic characteristics of the three groups are shown in
Table 1. Out of 58 patients (62 pregnancies) enrolled in the study,
20 (34.4%) were aPL positive (three women were positive for both
antibodies) and 7 (12%) had APS. In the aPL group, all patients
were nulliparous. None of the aPL and APS patients developed
thromboembolic events. The mean age was similar in the three
groups. At the first pre-conceptional examination, maternal SLE
was active in 25% of aPL group, in 14.2% of APS and 6.4% in
aPL-negative group. In aPL-positive patients and in APS, an
increased number of patients with previous lupus nephritis and
chronic hypertension with respect to aPL-negative patients, was
detected (P< 0.03) At pregnancy onset, 10 aPL-positive patients,
3 APS patients and 13 aPL-negative patients were on steroids with
an average prednisone dosage of 7.8mg/day (range 5–20).
Maternal outcome
In the observed 62 pregnancies, there were three (15%)
miscarriages in aPL patients, two in APS (28.5%) and six
(17.6%) in no aPL patients (equally distributed in the two study
groups) and one ectopic pregnancy. Fifty-one pregnancies
(82.2%) continued beyond the first trimester.
Overall, 16 episodes of flare were observed: eight in the aPL-
positive group, one in the APS and seven in aPL-negative group.
Regarding SLE flare, it was mild to moderate in 56.2% (9/16) of
the cases, with manifestations that did not require modification of
the therapy. Severe flare occurred in 43.7% (7/16) of the
pregnancies and was mainly characterized by nephritis.
In the group of 51 pregnancies that continued beyond the first
trimester, nine (9/51, 17.6%) have been complicated by pre-
eclampsia: 15% in aPL, 12.5% in APS and 14.7% in aPL
negative. Two of these patients developed haemolytic anemia,
elevated liver enzymes and low platelet count (HELLP) syndrome,
one in the aPL and one in APS group.
Fetal outcome
In our study population of 62 pregnancies, we had 51 deliveries
(82.2%): 85% (17/20) in the aPL positive and 75% (6/8) in the
APS and 82.3% (28/34) in aPL negative. There were 11
miscarriages before 10 weeks’ gestation. The pre-term delivery
rate was 29.4% (15 out of 51); 3 patients among aPL negative,
were pre-term delivery <34 weeks (Table 2).
There were no cases of neonatal lupus or congenital heart
block. Regarding birth weight, PI and the number of the neonates
with a birth weight less than 10th percentile (IUGR), there was no
statistically significant difference between the two groups. The
IUGR rate was 19.6% (10/51).
TABLE 1. Demographic and clinical characteristics of the patients
Patients aPLþ (n¼20) APS (n¼7) aPL (n¼31) P
Maternal age, mean S.D., yrs 36.64.10 37.123.18 34.5 5.57 NS
SLE length, mean S.D., yrs 6.25.61 6.54.23 6.0 5.83 NS
LAC, n (%) 14 (63.6) 5 0 -
ACA, n (%) 11 (50) 3 0 -
SSA/SSB, n (%) 7 (31.8) 2 7 (29.1) NS
SLE active, n (%) 5 (25) 1(14.2) 2 (6.4) NS
Prior lupus nephritis, n (%) 7 (35) 3 (42.8) 4 (12.9) NS
Chronic hypertension, n (%) 7 (35) 2 (28.5) 4 (12.9) 0.03
Pregnancies, n 20 8 34 NS
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Discussion
In SLE patients, the presence of aPLs is one of the risk factors
heralding complications and flare during pregnancy. The aPLs,
found in 30–80% of affected patients, have a role in the
pathogenesis of both maternal thromboembolic disease and
placental insufficiency with consequent pre-term labour, IUGR,
pre-eclampsia and ultimately fetal death [4–6].
Different therapeutic regimens (corticosteroids, aspirin, heparin
or a combination of them) have been evaluated in long-term
studies to improve fetal and maternal outcomes of aPL patients
[14–17], reaching a widespread agreement on the benefit of anti-
thrombotic prophylaxis.
Combined therapy with LWMH and LDA is considered as the
standard treatment for APS patients to reduce the incidence
of recurrent miscarriage, intrauterine growth restriction, pre-
eclampsia, HELLP syndrome and fetal death [18].
Thus, while previous thromboembolic events and negative
obstetric antecedents constitute a sufficient basis for prophylaxis,
there is no consensus on the fact that an anti-thrombotic
procedure may have a benefit in asymptomatic aPL-positive
patients in their first pregnancy [19].
Khamashta et al. [18] suggested that a prophylaxis exploiting
the anti-coagulant effect of LDA might play a fundamental role in
protecting pregnancies of aPL-positive but not symptomatic
nulliparous patients, influencing the prevalence of placental
accelerated atherosclerosis of these patients.
Recently, the involvement of endothelial dysfunction in the
pathogenesis of cardiovascular disease, hypertension and placen-
tal dysfunction during pregnancy has been recognized. Comparing
factors of vascular function between normal and SLE patients,
a significant reduction of the endothelial-mediated vasodilation,
index of precocious atherosclerosis in SLE patients, was
detected [20].
Up to date, there is a level of evidence evaluated as 9 in a scale
from 0 to 10 by the Task Force of the EULAR Standing
Committee for International Clinical Studies that LDA should be
used in adult SLE patients receiving corticosteroids, in those with
dosable aPL and in those with at least one traditional risk factor
for atherosclerotic disease, as primary prevention of thrombosis
and all the other manifestations of APS including abortion or fetal
loss [21].
Girardi et al. [22] in an experimental in vivo study recently
demonstrated that anti-coagulant effect can be considered
necessary but not sufficient in protecting aPL-induced fetal
losses. She suggested that complement system activation,
especially C3 and C5, is an important mechanism of anti-
phospholipid-induced pregnancy loss. C3 and C5 activation is
supposed to amplify pro-coagulant effects of aPL. Heparin
seemed to prevent aPL-induced pregnancy loss by inhibiting C3
and C5 activation rather than its anti-coagulant effect [22].
Our experience shows that the use of LWMH in the treatment
of asymptomatic aPL-positive nulliparous pregnancies brings
their incidence of fetal complications to be similar to the one
presented by standardly treated APS patients and moreover to
those patients who are aPL negative.
Moreover, the present case series shows that LMWH may
primarily prevent maternal complications, such as pre-eclampsia,
reducing its incidence to that presented by SLE pregnant aPL-
negative patients even when related risk factors are present as a
higher incidence of chronic hypertension and lupus nephritis.
This result is in agreement with previuos data that described
LMWH as protective for recurrent pre-eclampsia in non-SLE
pregnant patients [23].
In our work, LMWH was preferred to unfractioned heparin
(UFH) mainly because of its usefulness described in literature. In
a randomized pilot trial study, in pregnancy comparing LMWH,
specifically dalteparin, to UFH for the treatment of APS, found
higher successful pregnancy rate in the dalteparin group (69%)
(95% CI 39%, 91%), than in the UFH group (31%) (95% CI 9%,
61%) [24].
In conclusion, although the present study is limited by its
retrospective methodology, LMWH prophylaxis seems rather to
be a possible option for first pregnancy of SLE aPL-positive
patients who may reach maternal–fetal outcomes similar to aPL-
negative patients or to standard treated APS.
A prospective randomized study comparing outcomes of aPL-
positive pregnancies treated with LMWH and untreated aPL-
positive pregnancies is currently ongoing to better clarify if
LMWH might be in future considered as a tool for primary
prevention of uneventful aPL-induced outcomes of SLE pregnant
women.
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